About SOM Biotech
SOM Biotech is a company based in Barcelona (Spain) founded in 2009 by Raul Insa. SOM Biotech has raised $28.52 million across 3 funding rounds from investors including European Investment Bank and Prevail Partners. SOM Biotech offers products and services including SOM AI PRO and SOM3355. SOM Biotech operates in a competitive market with competitors including Biogen, GSK, Denali Therapeutics, Avidity Biosciences and Annexon, among others.
- Headquarter Barcelona, Spain
- Founders Raul Insa
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Som Innovation Biotech S.A.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$28.52 M (USD)
in 3 rounds
-
Latest Funding Round
$18.49 M (USD), Series B
Dec 04, 2023
-
Investors
European Investment Bank
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SOM Biotech
SOM Biotech offers a comprehensive portfolio of products and services, including SOM AI PRO and SOM3355.
Proprietary AI tool for predicting drug efficacy in rare disorders
Treatment for movement and psychiatric disorders in Huntington's Disease
People of SOM Biotech
Unlock access to complete
Unlock access to complete
Funding Insights of SOM Biotech
SOM Biotech has successfully raised a total of $28.52M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18.49 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $18.5M
-
First Round
First Round
(19 Jan 2017)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Series B - SOM Biotech | Valuation | European Investment Bank , Prevail Partners |
|
| Mar, 2019 | Amount | Series A - SOM Biotech | Valuation |
investors |
|
| Jan, 2017 | Amount | Seed - SOM Biotech | Valuation |
investors |
|
Investors in SOM Biotech
SOM Biotech has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include European Investment Bank and Prevail Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Founded Year | Domain | Location | |
|
Limited information is provided about Prevail Partners' activities.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SOM Biotech
Financial Statements - SOM Biotech
Som Biotech Comparisons
Competitors of SOM Biotech
SOM Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, GSK, Denali Therapeutics, Avidity Biosciences and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Frequently Asked Questions about SOM Biotech
SOM Biotech was founded in 2009 and raised its 1st funding round 8 years after it was founded.
SOM Biotech is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Raul Insa is the current CEO of SOM Biotech. They have also founded this company.
SOM Biotech is a funded company, having raised a total of $28.52M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.14M, raised on Jan 19, 2017.
Founded in 2009 and based in Barcelona, Spain, SOM Biotech operates in the biotechnology sector, focusing on rare disease treatments. A ligand-based in-silico platform is utilized for virtual compound screening to build a drug pipeline. This includes SOM0226 in phase II for TTR amyloidosis and SOM3355 in phase II for Huntingtons disease, alongside candidates targeting cystic fibrosis, glioblastoma, and Alzheimers disease.
SOM Biotech's top competitors include Alnylam, Sutro Biopharma and Annexon.
SOM Biotech offers SOM AI PRO and SOM3355.
SOM Biotech has 2 investors. Key investors include European Investment Bank, and Prevail Partners.